Lecanemab Clears Alzheimer's Plaques but Fails to Restore Brain's Waste Clearance System
Key Insights
Researchers from Osaka Metropolitan University found that lecanemab reduces amyloid-β (search) plaques but does not restore the brain's glymphatic waste clearance system within three months of treatment.
The study used DTI-ALPS imaging to measure glymphatic function and found no significant improvement in the index between pre-treatment and three months post-treatment.
The findings suggest that neuronal damage and clearance system deficits are already well-established by the time symptoms appear, highlighting the need for multi-targeted therapeutic approaches.
A new study from Osaka Metropolitan University reveals that lecanemab, the recently approved Alzheimer's drug designed to clear amyloid-β (search) plaques, fails to restore the brain's critical waste clearance system in the short term. The research, led by graduate student Tatsushi Oura and Dr. Hiroyuki Tatekawa, suggests that even after successful plaque reduction, the underlying neuronal damage and impaired brain function may be too advanced to reverse quickly.
Glymphatic System Dysfunction Persists Despite Plaque Clearance
The researchers examined the glymphatic system (search)—the brain's natural waste-removal network—in Alzheimer's patients before and after lecanemab treatment. In healthy individuals, this system circulates cerebrospinal fluid through spaces around arteries into brain tissue, where it mixes with interstitial fluid to remove metabolic waste, including amyloid-β (search). The term "glymphatic" derives from the glial cells that play a key role in this process.
However, in Alzheimer's patients, amyloid-β (search) accumulation causes arteries to stiffen, slowing fluid flow between brain tissue and cerebrospinal fluid. This disruption blocks the brain's ability to clear waste, triggering a cascade of neurodegenerative effects that lead to disease symptoms.
Study Methodology and Unexpected Results
The research team used a specialized imaging measure known as the DTI-ALPS index to track changes in glymphatic function. This diffusion tensor imaging technique serves as a noninvasive surrogate marker for glymphatic activity and is known to decline with normal aging and be significantly lower in Alzheimer's patients compared to cognitively normal individuals.
Despite expectations that lecanemab would improve waste clearance alongside plaque reduction, the researchers found no significant difference in the DTI-ALPS index between pre-treatment and three months after therapy. This finding challenges assumptions about the immediate benefits of anti-amyloid treatments on overall brain function.
Implications for Alzheimer's Treatment Strategy
The study's results underscore the complexity of Alzheimer's disease and suggest that targeting amyloid plaques alone may be insufficient for comprehensive treatment. "Even when Aβ is reduced by lecanemab, impairment of the glymphatic system (search) may not recover within the short-term," Oura explained.
The researchers concluded that while anti-amyloid drugs like lecanemab can lower plaque levels and slow cognitive decline, they may not restore lost brain function. By the time symptoms appear, both neuronal damage and waste clearance impairments are likely well-established and difficult to reverse, highlighting how Alzheimer's involves a network of biological problems beyond just plaque buildup.
Future Research Directions
The team plans to investigate factors that may influence treatment outcomes and glymphatic system (search) recovery. "In the future, we want to look at factors like age, the stage of the disease, and degree of lesions in the white matter to further understand the relationship between changes in the glymphatic system due to lecanemab treatment and the outcome of treatment," Oura said. "This will help understand the best way to administer treatment to patients."
The findings, published in the Journal of Magnetic Resonance Imaging, add to growing evidence that Alzheimer's is a multifaceted disease requiring therapies that target multiple biological pathways simultaneously. The research suggests that future treatment strategies may need to address not only amyloid clearance but also the restoration of the brain's waste removal systems and repair of established neuronal damage.